Peritoneal carcinomatosis, advanced stages of digestive and gynaecological cancers that invades the abdominal cavity

Relapses

More than 75% of relapses
within 5 years

Incidence

+200 000 new cases / year
in EU

Survival rate

50% of cases do not survive

5 years

A fluorescent tracer to assist the surgeon & maximize the completeness of tumor resection

Specific detection of tumor tissue

Tumor tissue is specifically detected through a glycosidic biomarker expressed by 90% of carcinoma (epithelial cancers). This biomarker is masked or invisible on healthy tissue. Our innovative probe makes it possible to discriminate between malignant and healthy tissue.

Administration mode

The nanoprobe is injected intraperitoneally in order to reach all nodules within the abdominal cavity even non-vascularized ones. These microscopic nodules are often responsibles for many relapses observed in those pathologies.

Detection of tumor microenvironment

Tumors' detection is made through accumulation of cancer-associated immune cells expressing CD176 (glycosidic biomarker) around the tumor tissue. Microscopic nodules' detection is possible even at their earliest development stages.

Targeting tracer for fluorescence-guided surgery

Highlighting tumor of all sizes
to prevent relapse of abdominal cancers

They support us

Emerging from a primary tumor site (ovaries, colon, pancreas, etc.), cancer cells spread through the peritoneal cavity resulting in peritoneal metastases (aka generalized abdominal cancers)

Meet the team

Mathilde Coustets, PhD

Chief Executive Officer

& Cofounder

Laurent Paquereau, PhD, HDR

Chief Scientific Officer

& Cofounder

Gwenael Ferron, MD, PhD, HDR

Chief Medical Officer

& Cofounder

Your privacy is very important to us. We will collect and use personal information solely with the objective of responding to your online request.

Contact us